Innokas' cooperation with Otivio started already in 2016. The “second generation device” received CE mark in 2018 after which the manufacturing of the system for Otivio started at Innokas Kempele factory. Innokas has been a part of the team which developed the 2.0 version of Otivio's product FlowOx.

‍

“A close collaboration between Innokas Medical and Cubist has been a vital part in making this project a success. By combining the skill sets of Innokas and Cubist, we have been able to cover the full chain of engineering, from cloud, connectivity and front end, to embedded, back end and manufacturing”, tells Iacob Mathiesen, working as CTO at Otivio AS.

‍

FlowOx 2.0, developed in co-creation between Norwegian company Otivio AS and Innokas Medical, is a clinically promising, patented and cost-efficient home treatment solution for Peripheral Arterial Disease (PAD). To meet the changing needs in the global markets, Otivio launched a re-design project with outcome target to co-create a next version of FlowOx with connectivity features.